UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Journal of infectious diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 12, pp. 1791 - 1801
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Index Medicus | Abridged Index Medicus | Major and Brief Reports
Journal Article
AIDS (London), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies | Index Medicus | AIDS/HIV
Journal Article
Journal of acquired immune deficiency syndromes (1999), ISSN 1525-4135, 05/2007, Volume 45, Issue 1, pp. 34 - 42
Low-density lipoprotein | Women | Highly active antiretroviral therapy | Lipids | High-density lipoprotein | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Fundamental and applied biological sciences. Psychology | Miscellaneous | Infectious diseases | Microbiology | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Virology | Cholesterol - blood | Didanosine - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Hispanic Americans - statistics & numerical data | Nevirapine - adverse effects | Tenofovir | Adenine - therapeutic use | Stavudine - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Dideoxynucleosides - adverse effects | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Organophosphonates - adverse effects | HIV Protease Inhibitors - therapeutic use | HIV-1 | Didanosine - therapeutic use | Multivariate Analysis | Lipoproteins, HDL - blood | United States | HIV Seropositivity - drug therapy | Nevirapine - therapeutic use | Lamivudine - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Stavudine - adverse effects | Lipids - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | HIV Seronegativity | Nelfinavir - therapeutic use | Fasting | Cross-Sectional Studies | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | European Continental Ancestry Group - statistics & numerical data | Benzoxazines - therapeutic use | Nelfinavir - adverse effects | African Continental Ancestry Group - statistics & numerical data | Triglycerides - blood | HIV Infections - drug therapy | Indinavir - adverse effects | Lipoproteins, LDL - blood | HIV Infections - metabolism | Indinavir - therapeutic use | Measurement | Complications and side effects | Dosage and administration | Blood lipids | Health aspects | HIV infection | Antiretroviral drugs | Drug therapy | Multivariate analysis | Human immunodeficiency virus--HIV | Index Medicus | AIDS/HIV
Journal Article
The Journal of infectious diseases, ISSN 0022-1899, 4/2013, Volume 207, Issue 7, pp. 1157 - 1165
T lymphocytes | HIV/AIDS | Telomeres | Antiretrovirals | HIV | Final causes | Cell lines | Nucleosides | Reverse transcriptase inhibitors | Carts | Disease risks | telomerase | aging | HIV infection | antiretroviral therapy | telomere | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Miscellaneous | Infectious diseases | Biological and medical sciences | Medical sciences | Virology | Humans | Middle Aged | Aging - drug effects | Antiretroviral Therapy, Highly Active - adverse effects | Male | Telomere - drug effects | Case-Control Studies | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Young Adult | Telomere Shortening | Adenine - adverse effects | HIV Infections - pathology | Time Factors | Polymerase Chain Reaction | Adult | Deoxycytidine - adverse effects | Female | Telomerase - metabolism | Dideoxynucleosides - adverse effects | Emtricitabine | Adenine - analogs & derivatives | Leukocytes, Mononuclear - drug effects | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Risk Factors | Cells, Cultured | Organophosphonates - adverse effects | HIV - pathogenicity | Enzyme Activation - drug effects | Regression Analysis | Telomere - enzymology | HIV Infections - drug therapy | Leukocytes, Mononuclear - enzymology | Telomerase - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Complications and side effects | Demographic aspects | Physiological aspects | Aging | Research | Telomerase | Index Medicus | Abridged Index Medicus
Journal Article
AIDS (London), ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article
Journal of human genetics, ISSN 1434-5161, 06/2013, Volume 58, Issue 6, pp. 317 - 326
drug-induced liver injury | pharmacogenomics | severe cutaneous adverse reactions | human leukocyte antigen | genome-wide association study | Life Sciences & Biomedicine | Genetics & Heredity | Science & Technology | HLA-DQ alpha-Chains - immunology | Stevens-Johnson Syndrome - immunology | Benzylamines - adverse effects | Humans | HLA Antigens - genetics | HLA-DQ alpha-Chains - genetics | Drug Hypersensitivity - genetics | Ticlopidine - adverse effects | Amoxicillin-Potassium Clavulanate Combination - adverse effects | Dideoxynucleosides - adverse effects | HLA-B Antigens - genetics | Skin - pathology | Skin - immunology | Pharmacogenetics | Diclofenac - analogs & derivatives | Diclofenac - adverse effects | Azetidines - adverse effects | HLA-B Antigens - immunology | HLA Antigens - immunology | Chemical and Drug Induced Liver Injury - genetics | Floxacillin - adverse effects | Genetic Markers | Chemical and Drug Induced Liver Injury - immunology | Drug Hypersensitivity - pathology | HLA-A Antigens - immunology | Stevens-Johnson Syndrome - genetics | Carbamazepine - adverse effects | Drug Hypersensitivity - immunology | Alleles | Allopurinol - adverse effects | HLA-A Antigens - genetics | Quinazolines - adverse effects | Skin - drug effects | Flucloxacillin | Risk groups | DQA1 protein | Allopurinol | Hypersensitivity | Liver | Drug development | Carbamazepine | Genetic screening | Ticlopidine | Quality of life | Side effects | Genetic markers | Abacavir | Histocompatibility antigen HLA | Pharmacogenomics | Index Medicus
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2010, Volume 55, Issue 1, pp. 49 - 57
HIV-1 | Efficacy | Abacavir/lamivudine | Tenofovir/emtricitabine | Cardiovascular | Renal | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Viral Load | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Young Adult | Glomerular Filtration Rate - drug effects | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | beta 2-Microglobulin - urine | Benzoxazines - adverse effects | Treatment Outcome | Retinol-Binding Proteins - urine | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations | Proteins | Antiretroviral drugs | Human immunodeficiency virus--HIV | Clinical trials | Adults | Drug therapy | Binding sites | Effectiveness studies | Index Medicus | AIDS/HIV
Journal Article
European journal of preventive cardiology, ISSN 2047-4881, 2016, Volume 23, Issue 2, pp. 214 - 223
epidemiology | AIDS | CVD risk prediction | HIV | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Blood Pressure | Genetic Predisposition to Disease | Prospective Studies | Age Factors | Risk Assessment | Lipoproteins, HDL - blood | Cholesterol - blood | HIV Infections - epidemiology | Humans | Middle Aged | Male | CD4 Lymphocyte Count | Models, Statistical | HIV Protease Inhibitors - therapeutic use | Smoking - epidemiology | Diabetes Mellitus - epidemiology | Sex Factors | Cardiovascular Diseases - epidemiology | Adult | Female | Dideoxynucleosides - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | Index Medicus
Journal Article
The lancet HIV, ISSN 2352-3018, 07/2018, Volume 5, Issue 7, pp. e357 - e365
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Tenofovir - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Drug-Related Side Effects and Adverse Reactions | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | Emtricitabine - administration & dosage | Dideoxynucleosides - administration & dosage | Heterocyclic Compounds, 4 or More Rings - administration & dosage | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | HIV Seropositivity | Tenofovir - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Heterocyclic Compounds, 4 or More Rings - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | HIV Infections - drug therapy | Aged | Sustained Virologic Response | Drug Substitution | Viral Load - drug effects | Index Medicus | AIDS/HIV
Journal Article